Vulvar childhood botryoid-type embryonal rhabdomyosarcoma

Summary

Vulvar childhood botryoid-type embryonal rhabdomyosarcoma (MONDO:0003995) is a disease. A subtype of childhood botryoid rhabdomyosarcoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	vulvar childhood botryoid-type embryonal rhabdomyosarcoma
Mondo ID	MONDO:0003995
DOID	DOID:6789
NCIT	C36098
UMLS	C1332946
MedGen	232056
GARD	0023768
Anatomy (UBERON)	UBERON:0000997
Is cancer (heuristic)	no

Also known as: childhood botryoid rhabdomyosarcoma of mammalian vulva · childhood botryoid-type embryonal rhabdomyosarcoma of the vulva · childhood sarcoma Botryoides of the vulva · mammalian vulva childhood botryoid rhabdomyosarcoma · vulvar childhood botryoid-type embryonal rhabdomyosarcoma

Disease family

This is a subtype of childhood botryoid rhabdomyosarcoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › sarcoma › soft tissue sarcoma › rhabdomyosarcoma › embryonal rhabdomyosarcoma › botryoid rhabdomyosarcoma › childhood botryoid rhabdomyosarcoma › vulvar childhood botryoid-type embryonal rhabdomyosarcoma

Related subtypes (1): childhood vagina botryoid rhabdomyosarcoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.